Promising Data from ALX Oncology's ASPEN-06 Trial
ALX Oncology has recently shared encouraging findings from the ASPEN-06 Phase 2 clinical trial, which evaluates the efficacy of its investigational drug evorpacept. This data was presented during the 2025 ASCO Gastrointestinal Cancers Symposium, illuminating the potential of evorpacept in treating patients with HER2-positive gastric cancer.
Key Findings of the Trial
The trial highlighted evorpacept as the first CD47 blocker that significantly demonstrates tumor responses combined with a manageable safety profile in a prospective trial. The results showed that evorpacept, used in conjunction with trastuzumab and paclitaxel, resulted in an Overall Response Rate (ORR) of 48.9% among patients who had confirmed HER2-positive expressions through fresh biopsy or circulating tumor DNA (ctDNA).
Benefits Among Patient Populations
According to the trial data, patients receiving evorpacept showed a median Duration of Response (mDOR) of 15.7 months, significantly better than the 9.1 months observed in the control group. This indicates that evorpacept could potentially offer a longer-lasting therapeutic benefit for patients diagnosed with advanced gastric cancer.
Safety and Tolerability
The safety assessments for evorpacept indicated that it is generally well-tolerated, with adverse events aligning with those seen in the conventional control group. This outcome suggests that evorpacept might enhance treatment efficacy without substantially increasing risk for patients.
Implications for Future Treatments
Dr. Kohei Shitara, who presented the findings, emphasized the significance of evorpacept's combination with other drugs for patients whose cancer has progressed despite prior HER2-targeted therapies. The results provide insight into the possibility of developing targeted therapy regimens that optimize the benefits of combined treatments.
Furthermore, ALX Oncology's Chief Medical Officer, Dr. Alan Sandler, stated that these findings reveal how crucial HER2-expression is as a biomarker for evorpacept's effectiveness when partnered with anti-HER2 therapies. This reinforces the company's strategy in tackling HER2-positive cancers.
Next Steps for ALX Oncology
With Fast Track designation from the FDA already in place for evorpacept concerning its application in HER2-positive gastric or gastroesophageal junction carcinomas, ALX Oncology is poised to advance these findings through future regulatory interactions. The emphasis will be on showcasing evorpacept’s clinical advantages and seeking approval for it as a viable therapy option.
Ongoing Clinical Trials
ALX Oncology continues to explore evorpacept in various phases for different cancer types beyond gastric cancer. Recent analyses also suggest positive outcomes for HER2-positive advanced breast cancer patients receiving evorpacept, showcasing its potential versatility in oncology.
Conference Call and Further Information
To relay the recent findings in more depth, ALX Oncology hosted a conference call that was accessible to investors and interested stakeholders. This meeting aimed to provide insights from professionals involved in the research and to outline future strategies for evorpacept.
Frequently Asked Questions
What is evorpacept?
Evorpacept is an investigational CD47-blocking therapeutic developed by ALX Oncology. It aims to enhance immune responses to combat cancer.
What were the main results of the ASPEN-06 trial?
The trial demonstrated that evorpacept led to an ORR of 48.9% in HER2-positive patients, with an mDOR of 15.7 months, indicating substantial efficacy.
How is evorpacept administered in the trial?
Evorpacept is being evaluated in combination with trastuzumab and paclitaxel, showing improved responses compared to traditional treatments.
What is the significance of the HER2 biomarker?
HER2 serves as a vital indicator for determining which patients may benefit most from evorpacept, guiding personalized treatment approaches.
Where can I find more information about ALX Oncology?
More details regarding ALX Oncology and their research can be found on their official website, which features updates on ongoing studies and clinical trials.
